Cantor Fitzgerald initiated coverage on Satellos Bioscience
$MSLE
Biotechnology: Pharmaceutical Preparations
Health Care
Cantor Fitzgerald initiated coverage of Satellos Bioscience with a rating of Overweight
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/6/2026 | $20.00 | Outperform | Leerink Partners |
| 3/11/2026 | Overweight | Cantor Fitzgerald |
6-K - Satellos Bioscience Inc. (0001421642) (Filer)
S-8 - Satellos Bioscience Inc. (0001421642) (Filer)
40-F - Satellos Bioscience Inc. (0001421642) (Filer)
TORONTO, April 09, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ:MSLE, TSX:MSCL) (" Satellos " or the " Company "), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it will participate in the Bloom Burton & Co. Healthcare Investor Conference taking place April 21-22, 2026, at the Metro Toronto Convention Centre in Toronto, Canada. Satellos Co-founder and CEO Frank Gleeson will provide a presentation on April 21 and along with Liz Williams, Chief Financial Officer, will participate in one-on-one meetings during the conference. 2026 Bloom Burton & Co. Healthcare Investor ConferenceFormat: Pres
Completed a US$57.2 million equity financing; commenced trading on the Nasdaq Global Market under the ticker "MSLE" on Feb. 6, 2026 Secured global regulatory clearances and initiated BASECAMP, a placebo-controlled Phase 2 clinical trial of SAT-3247 in boys aged 7 to less than 10 years living with Duchenne muscular dystrophy ("Duchenne" or "DMD") Presented initial functional outcomes from 56 days of treatment in TRAILHEAD (follow-on trial to CL-101) at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, demonstrating that grip strength improvements observed in CL-101 were maintained or improved in TRAILHEAD over an aggregate period of 9 to 13 months Reported pro
Interim observations from the Phase 2 TRAILHEAD study show continued improvement in handgrip strength, overall stability of elbow and shoulder strength in new dynamometry measurements Greater improvements in strength observed in participants with greater baseline muscle mass, further supporting evaluation in younger ages in ongoing BASECAMP studyProteomic analysis from the CL-101, 28-day Phase 1a/b study demonstrated reduction in established DMD biomarkers within two weeks of SAT-3247 administrationPreclinical data in facioscapulohumeral muscular dystrophy (FSHD) show enhanced muscle strength, supporting broader clinical potential of SAT-3247Enrollment ongoing in TRAILHEAD and BASECAMP
Leerink Partners initiated coverage of Satellos Bioscience with a rating of Outperform and set a new price target of $20.00
Cantor Fitzgerald initiated coverage of Satellos Bioscience with a rating of Overweight